PT500 – Shulgin Farm and the Future of Psyche...

ALS and ketamine therapy are at the center of this conversation with psychiatrist Dr. Michael Alpert and Peter Alberding, who was diagnosed with ALS in late 2023. Alpert is a Boston-area psychiatrist with experience in MDMA-assisted therapy research for PTSD and a private practic ...  Show more

Dr. Esme Dark joins Kyle Buller for a conversation on psychedelic therapy, somatic psychotherapy, and shadow work. Based in Australia, Dark is a clinical psychologist, somatic psychotherapist, and psychedelic therapist. She shares her perspective on Australia's authorized prescri ...  Show more

I had the pleasure of talking with Dr. Christina Rahm, who has an inspiring journey from a pharmaceutical executive to an advocate for integrating holistic health solutions with rigorous scientific methods. We dive into the impact of spirituality on wellness, the transformativ ...

Send a textThe path to FDA approved prescribable medicine has been a long and precarious one for psychedelics. However, recent reports by some of the major players in the psychedelic medicine space show promising results from clinical trials involving psilocybin and 5-MeO-DMT. In ...  Show more

In this episode of Huberman Lab Essentials, my guest is Dr. Karl Deisseroth, M.D., Ph.D., a clinical psychiatrist and professor of bioengineering and of psychiatry and behavioral sciences at Stanford University. We discuss his experiences as a clinician treating complex psychiatr ...  Show more

 In this episode, we meet with Dr. Suresh Muthukumaraswamy, an Associate Professor of Pharmacy in Auckland. Dr. Muthukumaraswamy discusses his early research, exploring the functional connectivity of substances like DMT and Ketamine. He proceeds to share insights into his brea ...